Graft-versus-Host Disease, the Graft-versus-Leukemia Effect, and Mixed Chimerism following Nonmyeloablative Stem Cell Transplantation

International Journal of Hematology

Volumn 78, Issue 3, 2003, Pages 195-207

  Slavin, Shimon ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Donor lymphocyte infusion; Graft versus host disease; Graft versus leukemia effects; Graft versus tumor effects; Mixed chimerism; Nonmyeloablative stem cell transplantation; Stem cell transplantation; Transplantation tolerance

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN; MINOR HISTOCOMPATIBILITY ANTIGEN; TUMOR ANTIGEN;

ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BENIGN TUMOR; BONE MARROW ABLATION; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CHEMOTHERAPY; CHIMERA; DONOR LYMPHOCYTE INFUSION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC SYSTEM TUMOR; HISTOCOMPATIBILITY; HISTOINCOMPATIBILITY; HUMAN; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE TRANSFUSION; MIXED CHIMERISM; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; RADIOTHERAPY; SOLID TUMOR; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; TUMOR CELL DESTRUCTION;

EID: 0142057522     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02983795     Document Type: Article

References (95)

1. Thomas ED. Marrow transplantation for malignant diseases. J Clin Oncol. 1983;1:517-531.
2. Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation: Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 1998;352:1087-1092.
3. Passweg JR, Rowlings PA, Armitage JO, et al. Report from the International Bone Marrow Transplant Registry and Autologous Blood and Marrow Transplant Registry: North America. In: Cecka JM,Teraskaki PI, eds. Clinical Transplants, 1995. Los Angeles, Calif: UCLA Tissue Typing Laboratory; 1996:117-127.
4. Bast CR. Principles of cancer biology: tumour immunology. In: DeVitta VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia, Pa: J. B. Lippincott; 1985:125-141.
5. Weiss L, Lubin I, Factorowich Y, et al. Effective graft-versusleukemia effects independent of graft-versus-host disease after T-cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma: role of cell therapy and recombinant IL-2. J Immunol. 1994;153:2562-2567.
6. Grillo-Lopez AJ, White CA, Dallaire BK, et al. Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Curr Pharm Biotechnol. 2000;1:1-9.
7. Thomas ED. The role of marrow transplantation in the eradication of malignant disease. Cancer. 1963;49:1963-1968.
8. Weiden PL, Sullivan KM, Fluornoy N, Storb R, Thomas ED. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med. 1981;304:1529-1533.
9. Weiden PL, Fluornoy N, Sanders JE, Sullivan KM, Thomas ED. Antileukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation. Transplantation. 1981;13:248-251.
10. Sullivan KM, Weiden PL, Storb R, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood. 1989;73:1720-1726.
11. Horowitz M, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555-562.
12. Sinkovics JG, Shullenberger CC, Howe CD. Prolongation and prevention of Rauscher virus mouse leukemia by spleen cells of naturally resistant or actively immunized mice. Clin Res. 1965;13:36-39.
13. Boranic M, Tonkovic I. Time pattern of the antileukemia effect of graft-versus-host reaction in mice. I: cellular events. Cancer Res. 1971;31:1140-1147,
14. Bortin MM, Truitt RL, Rimm AA, Bach FH. Graft-versus-leukaemia reactivity induced by alloimmunization without augmentation of graft-versus-host reactivity. Nature. 1979;281:490-491.
15. Slavin S, Weiss L, Morecki S, Weingensberg M. Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI). Cancer Immunol Immunother. 1981;11:155-161.
16. Truitt RL, Shih F-H, LeFever AV, Tempelis LD, Andreani M, Bortin MM. Characterization of alloimmunization-induced T lymphocytes reactivated against AKR leukemia in vitro and correlation with graft-vs-leukemia activity in vivo. J Immunol. 1983;131:2050-2058.
17. Meredith RF, O'Kunewick JP. Possibility of graft-vs-leukemia determinants independent of the major histocompatibility complex in allogeneic marrow transplantation. Transplantation. 1983;35:378-385.
18. Weiss L, Weigensberg M, Morecki S, et al. Characterization of effector cells of graft vs leukemia (GVL) following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia (BCL1). Cancer Immunol Immunother. 1990;31:236-242.
19. Truitt RL, Atasoylu AA. Impact of pretransplant conditioning and donor T cells on chimerism, graft-versus-host disease, graft-versus-leukemia reactivity, and tolerance after bone marrow transplantation. Blood. 1991;77:2515-2523.
20. 1 hybrids with spontaneous lymphosarcoma. J Immunol. 1984;132:997-1000.
21. Morecki S, Moshel Y, Gelfend Y, Pugatsch T, Slavin S. Induction of graft vs. tumor effect in a murine model of mammary adenocarcinoma. Int J Cancer. 1997;71:59-63.
22. Morecki S, Yacovlev E, Diab A, Slavin S. Allogeneic cell therapy for a murine mammary carcinoma. Cancer Res. 1998;58:3891-3895.
23. Eibl B, Schwaighofer H, Nachbaur D, et al. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood. 1996;88:1501-1508.
24. Ueno NT, Rondón G, Mirza NQ, et al. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol. 1998;16:986-993.
25. Or R, Ackerstein A, Nagler A, et al. Allogeneic cell-mediated immunotherapy for breast cancer after autologous stem cell transplantation: a clinical pilot study. Cytokines Cell Mol Ther. 1998;4:1-6.
26. Higano CS, Brixey M, Bryant EM. Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation: a case report of a probable graft-versusleukemia effect. Transfusion. 1990;50:175-178.
27. Bacigalupo A, Van Lint MT, Occhini D, et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood. 1991;77:1423-1428.
28. Weiss L, Reich S, Slavin S. Effect of cyclosporine A and methylprednisolone on the GVL effect across major histocompatibility barriers in mice following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1990;6:229-233.
29. Kapelushnik J, Or R, Aker M, et al. Allogeneic cell therapy of severe beta thalassemia major by displacement of host stem cells in mixed chimera by donor blood lymphocytes. Bone Marrow Transplant. 1996;19:96-98.
30. Kapelushnik J, Aker M, Or R, et al. Allogeneic cell therapy as a new modality for displacement of genetically abnormal stem cells as part of the conditioning for allogeneic bone marrow transplantation. In: Ringden O, Hobbs VR, Stewart CG, eds, Correction of Genetic Diseases by Transplantation IV. Middlesex, UK: Cogent Press; 1997:111-119.
31. Aker M, Kapelushnik J, Pugatsch T, et al. Donor lymphocyte infusions to displace residual host hematopoietic cells after allogeneic BMT for beta thalassemia major. J Pediatr Hematol Oncol. 1998;20:145-148.
32. Slavin S, Nagler A, Naparstek E, et al. Minitransplants and cell-based therapies for malignant and non-malignant disorders. Curr Opin Organ Transplant. 1999:4:184-188.
33. Slavin S, Or R, Naparstek E, Ackerstein A, Weiss L. Cellular-mediated immunotherapy of leukemia in conjunction with autologous and allogeneic bone marrow transplantation in experimental animals and man [abstract]. Blood. 1988;72(suppl 1):407a.
34. Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik Y, Or R. Allogeneic cell therapy for relapsed leukemia following bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol. 1995;23:1553-1562.
35. Slavin S, Naparstek E, Nagler A, et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse post allogeneic bone marrow transplantation. Blood. 1996;87:2195-2204.
36. Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76:2462-2465.
37. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients: European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood. 1995;86:2041-2050.
38. Collins RH, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433-444.
39. Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin JH. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med. 1994;330:100-106.
40. Mackinnon S, Papadopoulos EB, Carabassi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood. 1995;86:1261-1268.
41. Gubbay I, Collignon J, Koopman P, et al. A gene mapping to the sex-determining region of the mouse Y chromosome is a member of a novel family of embryologically expressed genes. Nature. 1990;346:245-250.
42. Pugatsch T, Oppenheim A, Slavin S. Improved single-step PCR assay for sex identification post-allogeneic sex-mismatched BMT. Bone Marrow Transplant. 1996:17:273-275.
43. Kawasaki ES, Clark SS, Coyne MY, et al. Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. Proc Natl Acad Sci USA. 1988;85:5698-5702.
44. De Witte T, Schattenberg A, Preijers F, Mensink E. Treatment of relapse in recipients of lymphocyte depleted grafts with infusion of lymphocytes of the original bone marrow donor. Exp Hematol. 1992;20:723.
45. Bar BM, Schattenberg A, Mensink EJ, et al. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J Clin Oncol. 1993;11:513-519.
46. Leber B, Walker IR, Rodrigues A, McBride JA, Carter R, Brian MC. Reinduction of remission of chronic myeloid leukemia by donor leukocyte transfusion following relapse after bone marrow transplantation: recovery complicated by initial pancytopenia and late dermatomyositis. Bone Marrow Transplant. 1993:12:405-407.
47. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994;330:1185-1191.
48. Kuzushima K, Yamamoto M, Kimura H, et al. Establishment of anti-Epstein-Barr virus (EBV) cellular immunity by adoptive transfer of virus specific cytotoxic T lymphocytes from an HLA matched sibling to a patient with severe chronic active EBV infection. Clin Exp Immunol. 1996;103:192-198.
49. Stockschlaeder M, Storb R, Pepe M, et al. A pilot study of low-dose cyclosporin for graft-versus-host prophylaxis in marrow transplantation. Br J Haematol. 1992;80:49-54.
50. Odom LF, August CS, Githens JH, et al. Remission of relapsed leukaemia during a graft-versus-host reaction: a "graft-versus-leukaemia reaction" in man? Lancet. 1978;2:537-538.
51. Slavin S, Fuks Z, Kaplan HS, Strober S. Transplantation of allogeneic bone marrow without graft-versus-host disease using total lymphoid irradiation. J Exp Med. 1978;147:963-972.
52. Weiss L, Reich S, Slavin S. Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders, I: treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL-2-activated cell-mediated immunotherapy. Cancer Invest. 1992;10:19-26.
53. Johnson BD, Drobyski WR, Truitt RL. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. Bone Marrow Transplant. 1993;11:329-336.
54. Naparstek E, Or R, Nagler A, et al. T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br J Haematol. 1995;89:506-515.
55. Naparstek E, Nagler A, Or R, Slavin S. Allogeneic cell mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic BMT for hematological malignancies: North America. In: Cecka JM, Teraskaki PI, eds. Clinical Transplants, 1995. Los Angeles, Calif: UCLA Tissue Typing Laboratory; 1996:281-290.
56. van Rhee F, Lin F, Cullis JO, et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood. 1994;83:3377-3383.
57. Sullivan KM, Storb R, Buckner CD, et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med. 1989;320:828-834.
58. Rosenberg SA. The immunotherapy and gene therapy of cancer. J Clin Oncol. 1992;10:180-192.
59. Reisner Y, Kapoor N, Kirkpatrick D, et al. Transplantation for severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood. 1983;61:341-348.
60. Waldmann H, Polliack A, Hale G, et al. Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet. 1984;2:483-485.
61. Reisner Y, Martelli MF. Bone marrow transplantation across HLA barriers by increasing the number of transplanted cells. Immunol Today. 1995;16:437-440.
62. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998;339:1186-1193.
63. Slavin S, Strober S. Spontaneous murine B-cell leukemia. Nature. 1978;272:624-626.
64. Slavin S, Weiss L, Morecki S, et al. Ultrastructural, cell membrane and cytogenetic characteristics of B-cell leukemia (BCL1), a murine model of chronic lymphocytic leukemia. Cancer Res. 1981;41:4162-4166.
65. Raanani P, Dazzi F, Sohal J, et al. The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. Br J Haematol. 1997;99:945-950.
66. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood. 1997;90:3204-3213.
67. Cobold S, Martin G, Waldmann H. Monoclonal antibodies for the prevention of graft-versus-host disease and marrow graft rejection. Transplantation. 1986;42:239-247.
68. Hale G, Xia MQ, Tighe HP, Dyer MJS, Waldmann H. The CAMPATH-1 antigen (CDw52). Tissue Antigens. 1990;35:118-127.
69. Slavin S, Waldmann H, Or R, et al. Prevention of graft-versus-host disease in allogeneic bone marrow transplantation for leukemia by T cell depletion in vitro prior to transplantation. Transplant Proc. 1985;17:465-467.
70. Naparstek E, Or R, Nagler A, et al. Allogeneic BMT for leukemia using Campath-1 monoclonal antibodies and post transplant alloimmunization with donor lymphocytes [abstract]. Exp Hematol. 1993;21:1061. Abstract 189.
71. Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia response from graft-versus-host disease. Blood. 1995;86:1261-1268.
72. Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997;276:1719-1724.
73. Slavin S, Strober S, Fuks Z, Kaplan HS. Long-term survival of skin allografts in mice treated with fractionated total lymphoid irradiation. Science. 1976;193:1252-1254.
74. Slavin S, Fuks Z, Kaplan HS, Strober S. Transplantation of allogeneic bone marrow without graft-versus-host disease using total lymphoid irradiation. J Exp Med. 1978;147:963-972.
75. Slavin S. Total lymphoid irradiation (TLI). Immunol Today. 1987;8:88-92.
76. Giralt S, Cohen A, Mehra R, et al. Preliminary results of fludarabine/melphalan or 2CDA/melphalan as preparative regimens for allogeneic progenitor cell transplantation in poor candidates for conventional myeloablative conditioning [abstract]. Blood. 1997;90(suppl 1):1853a.
77. Slavin S, Nagler A, Naparstek E, et al. Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756-763.
78. Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998;16:2817-2824.
79. Carella AM, Giralt S, Slavin S. Low intensity regimens with allogeneic hematopoietic stem cell transplantation as treatment of hematologic neoplasia. Haematologica. 2000;85:304-313.
80. Carella AM, Champlin R, Slavin S, McSweeney P, Storb R. Miniallografts: ongoing trials in humans. Bone Marrow Transplant. 2000;25:345-350.
81. Nagler A, Slavin S, Varadi G, Naparstek E, Samuel S, Or R. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant. 2000;25:1021-1028.
82. Nagler A, Ackerstein A, Kapelushnik J, Or R, Naparstek E, Slavin S. Donor lymphocyte infusion post-non-myeloablative allogeneic peripheral blood stem cell transplantation for chronic granulomatous disease. Bone Marrow Transplant. 1999;24:339-342.
83. Kapelushnik J, Or R, Slavin S, Nagler A. Fludarabine based protocol for BMT in Fanconi anemia. Bone Marrow Transplant. 1997;29:1109-1110.
84. Aker A, Varadi G, Slavin S, Nagler A. Fludarabine-based protocol for human umbilical cord blood transplantation in children with Fanconi's anemia. J Pediatr Hematol Oncol. 1999;21:237-239.
85. Kapelushnik J, Aker M, Pugatsch T, Samuel S, Slavin S. Bone marrow transplantation from a cadaveric donor. Bone Marrow Transplant. 1998;21:857-858.
86. Nagler A, Aker M, Or R, et al. Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation. Exp Hematol. 2001;29:362-370.
87. Kottaridis PD, Milligan DW, Chopra R, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood. 2000;96:2419-2425.
88. Slavin S, Ackerstein A, Morecki S, Gelfand Y, Cividalli G. Immunotherapy of relapsed resistant chronic myelogenous leukemia post allogeneic bone marrow transplantation with alloantigens pulsed donor lymphocytes. Bone Marrow Transplant. 2001;28:795-798.
89. Falkenburg JHF, Faber LM, van den Elshout M, et al. Generation of donor-derived antileukemic cytotoxic T-lymphocyte responses for treatment of relapsed leukemia after allogeneic HLA-identical bone marrow transplantation. J Immunother. 1993;14:305-309.
90. Slavin S, Nagler A, Varadi G, Or R. Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis. Exp Hematol. 2000;28:853-857.
91. Childs RW, Clave E, Tisdale J, Plante M, Hensel N, Barrett J. Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect. J Clin Oncol. 1999;17:2044-2049.
92. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000;343:750-758.
93. Slavin S. Immunotherapy of cancer with alloreactive lymphocytes. Lancet Oncol. 2001;2:491-498.
94. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia with myeloablative therapy. Blood. 1997;89:4531-4536.
95. Slavin S, Nagler A, Naparstek E, et al. Successful replacement of conventional bone marrow transplantation with high-dose chemoradiotherapy with well tolerated nonmyeloablative conditioning in preparation for the treatment of malignant and nonmalignant diseases [abstract]. Blood. 1997;90:534a.